CLINICAL TRIALS PROFILE FOR CEFPROZIL

All Clinical Trials for CEFPROZIL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00778245 ↗	Bioequivalence Study of Cefprozil Tablets, USP 500 mg Undef Fed Conditions	Completed	Ranbaxy Laboratories Limited	N/A	2005-05-01	The objective of this study is to assess the single - dose relative bioavailability of Ranbaxy and Bristol-Myers Squibb Company (CEFZIL ®) 500 mg cefprozil tablets, under fed conditions.
NCT00778557 ↗	Bioequivalence Study of Cefprozil 250 mg/ 5mL Powder For Oral Suspension Under Fasting Conditions	Completed	Ranbaxy Laboratories Limited	N/A	2005-06-01	The study was conducted as a blinded, randomized, 3-way crossover study to compare the single-dose relative bioavailability of Cefprozil 250 mg/5 mL Oral suspension versus Cefzil TM Powder for Oral Suspension (250 mg/5 mL) following one 5 mL dose under fasting conditions
NCT00778739 ↗	Bioequivalence Study of Cefprozil 250 mg/ 5mL Powder For Oral Suspension Under Fed Conditions	Completed	Ranbaxy Laboratories Limited	N/A	2005-06-01	The study was conducted as an open-label, randomized, 2-way crossover study to compare the single-dose relative bioavailability of Cefprozil 250 mg/5 mL Oral suspension versus Cefzil TM Powder for Oral Suspension (250 mg/5 mL) following one 5 mL dose under fed conditions
NCT00778778 ↗	Bioequivalence Study of Cefprozil Tablets, USP 500 mg Under Fasting Conditions	Completed	Ranbaxy Laboratories Limited	N/A	2005-05-01	The objective of this study was to assess the single-dose relative bioavailability of Ranbaxy and Bristol-Myers Squibb Company (CEFZIL ®) 500 mg cefprozil tablets, under fasting conditions.
NCT00835354 ↗	Cefprozil for Oral Suspension 250 mg/5 mL, Non-fasting	Completed	Teva Pharmaceuticals USA	Phase 1	2004-05-01	The objective of this study is to compare the relative bioavailability of cefprozil for oral suspension 250 mg/5 mL (TEVA Pharmaceuticals USA) with that of CEFZIL® for Oral Suspension 250 mg/5 mL (Bristol-Myers Squibb) in healthy, non-smoking adults under non-fasting conditions.
NCT00835614 ↗	Cefprozil for Oral Suspension 250 mg/5 mL, Fasting	Completed	Teva Pharmaceuticals USA	Phase 1	2004-04-01	The objective of this study is to compare the relative bioavailability of cefprozil for oral suspension 250 mg/5 mL (TEVA Pharmaceuticals USA) with that of CEFZIL® for Oral Suspension 250 mg/5 mL (Bristol-Myers Squibb) in healthy, non-smoking adults under fasting conditions.

Clinical Trial Conditions for CEFPROZIL

Condition Name

Condition Name for CEFPROZIL
Intervention	Trials
Healthy	12
Healthy Volunteers	1
Osteomyelitis	1

Condition MeSH

Condition MeSH for CEFPROZIL
Intervention	Trials
Disease	2
Osteomyelitis	1
Malnutrition	1

Clinical Trial Locations for CEFPROZIL

Trials by Country

Trials by Country for CEFPROZIL
Location	Trials
United States	7
Canada	4
China	1

Trials by US State

Trials by US State for CEFPROZIL
Location	Trials
Missouri	4
Texas	2
Kentucky	1

Clinical Trial Progress for CEFPROZIL

Clinical Trial Phase

Clinical Trial Phase for CEFPROZIL
Clinical Trial Phase	Trials
Phase 1	9
N/A	4
Early Phase 1	1

Clinical Trial Status

Clinical Trial Status for CEFPROZIL
Clinical Trial Phase	Trials
Completed	13
Terminated	1

Clinical Trial Sponsors for CEFPROZIL

Sponsor Name

Sponsor Name for CEFPROZIL
Sponsor	Trials
Teva Pharmaceuticals USA	4
Sandoz	4
Ranbaxy Laboratories Limited	4

Sponsor Type

Sponsor Type for CEFPROZIL
Sponsor	Trials
Industry	12
Other	4